Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PTH and interactions with bisphosphonates.

J A Gasser1, M Kneissel, J S Thomsen

  • 1Novartis Pharma AG, Basel, Switzerland.

Journal of Musculoskeletal & Neuronal Interactions
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcified cartilage differs in patients with end-stage primary osteoarthritis and secondary osteoarthritis due to rheumatoid arthritis of the hip joint.

Scandinavian journal of rheumatology·2021
Same author

CARGEL Bioscaffold improves cartilage repair tissue after bone marrow stimulation in a minipig model.

Journal of experimental orthopaedics·2020
Same author

Modeling-based bone formation transforms trabeculae to cortical bone in the sclerotic areas in Buschke-Ollendorff syndrome. A case study of two females with LEMD3 variants.

Bone·2020
Same author

Therapy for musculoskeletal disorders.

Journal of orthopaedic translation·2018
Same author

Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.

Journal of musculoskeletal & neuronal interactions·2017
Same author

Local bone loss in patients with anti-citrullinated peptide antibody and arthralgia, evaluated with high-resolution peripheral quantitative computed tomography.

Scandinavian journal of rheumatology·2017

Bisphosphonates like alendronate can reduce the bone-building effects of anabolic drugs (SDZ PTS 893). A washout period did not fully restore the response, suggesting a long-term interaction impacting bone mass measurements.

Area of Science:

  • Bone biology and pharmacology
  • Skeletal remodeling and drug interactions

Background:

  • Bisphosphonates are widely used antiresorptive agents for osteoporosis.
  • Anabolic agents like parathyroid hormone (PTH) and SDZ PTS 893 stimulate bone formation.
  • The interaction between these drug classes is not fully understood.

Purpose of the Study:

  • To investigate the impact of bisphosphonate treatment on the anabolic response to SDZ PTS 893 in mature rats.
  • To determine if a washout period can reverse any observed blunting of the anabolic effect.

Main Methods:

  • Skeletally mature rats received alendronate (bisphosphonate) or vehicle for 16 weeks.
  • Rats were challenged with a high dose of SDZ PTS 893, with some undergoing an 8-week washout period.
  • Bone mass was assessed using DEXA and pQCT, and biomechanical testing was performed.

Related Experiment Videos

Main Results:

  • Alendronate significantly blunted the anabolic response to SDZ PTS 893 in tibia and femur, but not lumbar vertebra.
  • A washout period was insufficient for full recovery of the anabolic response.
  • Serial pQCT measurements indicated interactions occurring early in PTH treatment and persistent effects over time.

Conclusions:

  • Bisphosphonate administration can diminish the efficacy of anabolic agents like SDZ PTS 893, potentially due to physico-chemical interactions with bone matrix.
  • Clinical implications include potential delays in bone mass measurements and reduced anabolic response in bisphosphonate-treated patients.
  • While a delay in response is possible, the protective effects of bisphosphonates may outweigh this concern in certain contexts.